Solnul Replication Trial Reproduces Bifidobacterium and Stool Form Effects
Key Takeaways
- Trial design replicated dose, duration, and population from a prior study, aiming to test reproducibility rather than generate disparate endpoints across heterogeneous protocols.
- Solnul significantly increased Bifidobacterium relative abundance versus placebo and improved bowel habit metrics (more normal stools; fewer no-BM days in exploratory analyses).
A 4-week trial of 3.5 g of Solnul resistant potato starch increased Bifidobacterium and normal stools versus placebo.
MSP Starch Products Inc. on November 4 announced the publication of a replication trial of Solnul, its prebiotic resistant potato starch, in the journal Nutrients, according to a company press release.1
"While replication clinical trials are important to build confidence in the health benefits of a prebiotic, they are atypical with sequential studies often designed to answer very different questions," stated Edward Deehan, PhD, assistant professor at the University of Nebraska–Lincoln and co-corresponding author of the publication. "That is why this replication trial with Solnul is so unique and important, as by using the same design it confirms what health benefits are consistent and reproducible." The paper was published October 27.2
What Did the Trial Test?
The 4-week, randomized, double-blind, placebo-controlled trial enrolled 74 healthy adults aged 18 to 69 in Guelph, Ontario, and compared 3.5 g of Solnul daily with a corn starch placebo. Seventy participants were included in the per-protocol analysis. The authors said the study repeated the dose, duration, and population of a 2023 trial that also included a 7 g arm.2,3 Akkermansia relative abundance was the primary endpoint in the replication trial.
What Were the Results?
Compared with placebo, Solnul increased Bifidobacterium relative abundance (p = 0.049) and the number of normal stools (p = 0.0077), both key secondary endpoints. Participants taking Solnul also had fewer days without a bowel movement than the placebo group in an exploratory analysis, and gastrointestinal symptom scores did not change in the Solnul group. No serious adverse events occurred.
The primary endpoint was not met. Akkermansia changes did not differ from placebo (p = 0.49), though levels in the Solnul group rose relative to their own baseline. The authors said the use of different microbiome extraction and sequencing methods than in the earlier trial likely contributed to a weaker Bifidobacterium response and the lack of an Akkermansia difference between groups.
In the 2023 trial, 3.5 g of Solnul significantly increased Bifidobacterium (p = 0.038) and Akkermansia (p = 0.014) compared with placebo after outliers were removed, and lowered constipation- and diarrhea-associated bowel movements.
What Did the Company Say About the Findings?
“Credible science builds confidence,” stated Jason Bush, PhD, chief scientific officer of MSP Starch Products Inc. “By reproducing our findings, we're giving brands a stronger foundation for their products and consumers more reason to trust Solnul for the prebiotic outcomes and digestive comfort they're looking for.”
In a Nutritional Outlook video interview at SupplySide Global, Bush explained that many ingredient companies rely on a patchwork of studies with similar doses and populations but different outcomes, and that this trial with Solnul measured the same dose, duration, and population twice in independent groups.4 He said the results showed consistent bifidogenic and stool form effects, making Solnul “one of the only ingredients out there” to reproduce these prebiotic effects.
What Are the Study’s Disclosures and Limits?
The replication reports no external funding, and Bush is employed by MSP Starch Products. The 2023 trial was funded by the company, and a sister company, McPharma Biotech, holds relevant patents. Deehan reported consulting fees from companies involved in dietary fiber manufacturing but none from MSP Starch.
The authors said the sample size calculation may have overestimated the expected Akkermansia effect, and that too few participants may have been enrolled to detect it. They also noted that the gastrointestinal benefits were observed in healthy adults, so relevance in clinical populations remains to be determined. Data are available on request with the company’s permission.
References
- MSP Starch Products Inc. Solnul reproduces clinical outcomes, strengthening confidence in the prebiotic ingredient’s ability to enhance the microbiome and support digestive comfort. Press release. November 4, 2026. Accessed November 19, 2026.
https://www.newswire.ca/news-releases/solnul-r-reproduces-clinical-outcomes-strengthening-confidence-in-the-prebiotic-ingredient-s-ability-to-enhance-the-microbiome-and-support-digestive-comfort-849255564.html - Bush JR, Iwuamadi I, Deehan EC. Examining the gastrointestinal effects of Solnul, a prebiotic resistant potato starch: a replication randomized, double-blind, placebo-controlled clinical trial in healthy adults. Nutrients. 2026;18(21):3538. doi:10.3390/nu18213538
- Bush JR, Baisley J, Harding SV, Alfa MJ. Consumption of Solnul™ resistant potato starch produces a prebiotic effect in a randomized, placebo-controlled clinical trial. Nutrients. 2023;15(7):1582. doi:10.3390/nu15071582
- Bush J, Jacobus N. Solnul new clinical study. Accessed November 19, 2026.
https://www.nutritionaloutlook.com/shorts/solnul-new-clinical-study
Related to this article








